TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INCIDENCE OF TRAUMA CASES
4.2.2 RISING ADOPTION OF SEDENTARY LIFESTYLE
4.3 RESTRAINTS
4.3.1 RISKS ASSOCIATED WITH THROMBOSIS DRUGS
4.4 OPPORTUNITIES
4.4.1 NEW PRODUCT APPROVALS AND LAUNCHES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL THROMBUS TREATMENT MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 DEMAND-SUPPLY GAP ANALYSIS
5.3.4 IMPACT ON PRICING
5.4 NUMBER OF PROCEDURES FOR PULMONARY EMBOLISM
6 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE
6.1 OVERVIEW
6.2 ATRIAL THROMBUS
6.3 VENOUS THROMBUS
7 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 MEDICAL THERAPY
7.3 SURGERY
7.4 OTHERS
8 GLOBAL THROMBUS TREATMENT MARKET, BY REGION
8.1 OVERVIEW
8.1.1 NORTH AMERICA
8.1.1.1 US
8.1.1.2 CANADA
8.1.2 EUROPE
8.1.2.1 GERMANY
8.1.2.2 UK
8.1.2.3 FRANCE
8.1.2.4 ITALY
8.1.2.5 SPAIN
8.1.2.6 REST OF EUROPE
8.1.3 ASIA-PACIFIC
8.1.3.1 JAPAN
8.1.3.2 CHINA
8.1.3.3 INDIA
8.1.3.4 AUSTRALIA
8.1.3.5 SOUTH KOREA
8.1.3.6 REST OF ASIA-PACIFIC
8.1.4 REST OF THE WORLD
8.1.4.1 MIDDLE EAST
8.1.4.2 AFRICA
8.1.4.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL THROMBUS TREATMENT MARKET
9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL THROMBUS TREATMENT MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES
9.6.2 PARTNERSHIP/COLLABORATION
9.7 MAJOR PLAYERS FINANCIAL MATRIX
9.7.1 SALES (USD MILLION), 2021
9.7.2 R&D (USD MILLION), 2021
10 COMPANY PROFILES
10.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL ANALYSIS
10.1.3 PRODUCTS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 SANOFI
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 PFIZER INC.
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 KEY STRATEGIES
10.4 BAYER AG
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 ANGIODYNAMICS.
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 BRISTOL-MYERS SQUIBB COMPANY
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIES
10.8 ASPEN HOLDINGS
10.8.1 COMPANY OVERVIEW
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIES
10.9 JOHNSON & JOHNSON SERVICES, INC.
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.9.6 KEY STRATEGIES
10.10 DAIICHI SANKYO COMPANY, LIMITED
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
LIST OF TABLESTABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 NUMBER OF PROCEDURES FOR PULMONARY EMBOLISM, BY REGION (2021)
TABLE 4 GLOBAL THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 5 GLOBAL THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY REGION, 2018–2030 (USD MILLION)
TABLE 6 GLOBAL THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 7 GLOBAL THROMBUS TREATMENT MARKET, FOR RIGHT ATRIAL THROMBUS, BY REGION, 2018–2030 (USD MILLION)
TABLE 8 GLOBAL THROMBUS TREATMENT MARKET, FOR LEFT ATRIAL THROMBUS, BY REGION, 2018–2030 (USD MILLION)
TABLE 9 GLOBAL THROMBUS TREATMENT MARKET, FOR VENOUS THROMBUS, BY REGION, 2018–2030 (USD MILLION)
TABLE 10 GLOBAL THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 11 GLOBAL THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY REGION, 2018–2030 (USD MILLION)
TABLE 12 GLOBAL THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 13 GLOBAL THROMBUS TREATMENT MARKET, FOR ANTIPLATELETS BY TYPE, 2018–2030 (USD MILLION)
TABLE 14 GLOBAL THROMBUS TREATMENT MARKET, FOR ANTICOAGULANTS BY TYPE, 2018–2030 (USD MILLION)
TABLE 15 GLOBAL THROMBUS TREATMENT MARKET, FOR THROMBOLYTICS BY TYPE, 2018–2030 (USD MILLION)
TABLE 16 GLOBAL THROMBUS TREATMENT MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)
TABLE 17 GLOBAL THROMBUS TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)
TABLE 18 GLOBAL: THROMBUS TREATMENT MARKET, BY REGION, 2018–2030 (USD MILLION)
TABLE 19 NORTH AMERICA: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 20 NORTH AMERICA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 21 NORTH AMERICA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
TABLE 22 NORTH AMERICA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 23 NORTH AMERICA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 24 US: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 25 US: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 26 US: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018-2030
TABLE 27 US: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 28 CANADA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 29 CANADA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
TABLE 30 CANADA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 31 CANADA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 32 EUROPE: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 33 EUROPE: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 34 EUROPE: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 35 EUROPE: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 36 EUROPE: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 37 GERMANY: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 38 GERMANY: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 39 GERMANY: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 40 GERMANY: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 41 UK: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 42 UK: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 43 UK: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 44 UK: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 45 FRANCE: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 46 FRANCE: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 47 FRANCE: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 48 FRANCE: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 49 ITALY: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 50 ITALY: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 51 ITALY: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 52 ITALY: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 53 SPAIN: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 54 SPAIN: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 55 SPAIN: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 56 SPAIN: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 57 REST OF EUROPE: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 58 REST OF EUROPE: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 59 REST OF EUROPE: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 60 REST OF EUROPE: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TYPE, 2018–2030 (USD MILLION)
TABLE 61 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 62 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 63 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
TABLE 64 ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 65 ASIA-PACIFIC: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 66 JAPAN: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 67 JAPAN: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68 JAPAN: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 69 JAPAN: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 70 CHINA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 71 CHINA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72 CHINA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 73 CHINA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 74 INDIA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 75 INDIA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76 INDIA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 77 INDIA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 78 AUSTRALIA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 79 AUSTRALIA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80 AUSTRALIA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 81 AUSTRALIA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 82 SOUTH KOREA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 83 SOUTH KOREA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84 SOUTH KOREA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 85 SOUTH KOREA: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 86 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 87 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 89 REST OF ASIA-PACIFIC: THROMBUS TREATMENT MARKET FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 90 REST OF THE WORLD: THROMBUS TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 91 REST OF THE WORLD: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 92 REST OF THE WORLD: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
TABLE 93 REST OF THE WORLD: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 94 REST OF THE WORLD: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 95 MIDDLE EAST: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 96 MIDDLE EAST: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
TABLE 97 MIDDLE EAST: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 98 MIDDLE EAST: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 99 AFRICA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 100 AFRICA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
TABLE 101 AFRICA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 102 AFRICA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 103 LATIN AMERICA: THROMBUS TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)
TABLE 104 LATIN AMERICA: THROMBUS TREATMENT MARKET, FOR ATRIAL THROMBUS, BY TYPE, 2018-2030
TABLE 105 LATIN AMERICA: THROMBUS TREATMENT MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 106 LATIN AMERICA: THROMBUS TREATMENT MARKET, FOR MEDICAL THERAPY, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 107 MAJOR PLAYERS IN THE GLOBAL THROMBUS TREATMENT MARKET
TABLE 108 MOST ACTIVE PLAYERS IN THE GLOBAL THROMBUS TREATMENT MARKET
TABLE 109 PRODUCT APPROVALS/PRODUCT LAUNCHES
TABLE 110 PARTNERSHIP/COLLABORATION
TABLE 111 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 112 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 113 SANOFI: PRODUCTS OFFERED
TABLE 114 PFIZER INC.: PRODUCTS OFFERED
TABLE 115 BAYER AG: PRODUCTS OFFERED
TABLE 116 BAYER AG: KEY DEVELOPMENTS
TABLE 117 ANGIODYNAMICS.: PRODUCTS OFFERED
TABLE 118 ANGIODYNAMICS.: KEY DEVELOPMENTS
TABLE 119 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
TABLE 120 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
TABLE 121 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS
TABLE 122 ASPEN HOLDINGS: PRODUCTS OFFERED
TABLE 123 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
TABLE 124 JOHNSON & JOHNSON SERVICES INC.: KEY DEVELOPMENTS
TABLE 125 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED
| ※参考情報 血栓治療は、血管内に形成された血栓を取り除く、または解消するための治療方法を指します。血栓は、血液が固まることによって形成され、動脈や静脈に血流を妨げることがあり、これにより様々な疾患が引き起こされることがあります。例えば、心筋梗塞や脳梗塞などの重大な病態は、血栓による血流障害が原因となって発生します。このため、血栓治療は非常に重要な医療分野であり、様々な治療法が開発されています。 血栓治療にはいくつかの種類があり、主に以下のような方法が用いられます。 まず第一に、抗凝固療法があります。これは、血液の凝固を抑える薬剤を用いる治療法であり、主に静脈血栓症や心房細動による脳梗塞予防に用いられます。代表的な薬剤にはワルファリンやダビガトラン、アピキサバンなどがあります。これらの薬剤は、血液が固まる過程を妨げることで、血栓の形成を防ぎます。 次に、抗血小板療法があります。これは、血小板が集合して血栓を形成するのを防ぐための治療法であり、主に心筋梗塞や脳梗塞の予防に用いられます。代表的な抗血小板薬にはアスピリンやクロピドグレルがあります。これらの薬剤は、血小板の機能を抑制することで、血栓の形成を防ぎます。 さらに、血栓溶解療法も重要な治療法の一つです。これは、既に形成された血栓を溶解するための薬剤を使用する方法であり、特に急性心筋梗塞や脳梗塞の緊急治療に用いられます。代表的な薬剤にはナシルテプラーゼやウロキナーゼがあり、これらは血栓を構成するフィブリンを分解する作用があります。 また、カテーテル治療も血栓治療において有用です。カテーテルを用いて血栓を直接取り除く方法や、薬剤を局所的に投与する方法があります。これには機械的血栓除去法が含まれ、特に脳梗塞の場合においては、多くの効果が得られています。 血栓治療の用途としては、心筋梗塞や脳梗塞、深部静脈血栓症（DVT）、肺塞栓症などが挙げられます。これらの疾患は、血栓によって血流が妨げられることで発症し、適切な治療が施されない場合には、致命的な結果を招く可能性があります。したがって、迅速な血栓治療が求められます。 関連技術としては、医療機器の進化が挙げられます。例えば、血栓除去用のデバイスやカテーテルの改良により、手術の侵襲が軽減され、治療の成功率が向上しています。また、画像診断技術の進歩によって、血栓の正確な位置や大きさを把握しやすくなり、より適切な治療が行えるようになっています。 さらに、血栓治療における個別化医療が注目されています。患者一人ひとりの病状や遺伝的背景に応じて、最適な治療法を選択する試みが進行中です。これによって、治療の効果が最大化されることが期待されています。 結論として、血栓治療は多岐にわたる治療法があり、急性の疾患から予防まで幅広く対応可能です。今後も研究が進むことで、より安全で効果的な治療法が開発され、人々の健康と生活の質が向上することが期待されています。血栓治療は、心血管疾患の予防・治療において非常に重要な役割を果たし続けるでしょう。 |
